Related Experiment Videos
6;9 translocation in myelodysplastic syndrome
M Y Shapira1, B Hirshberg, G Amir
1Division of Medicine, Hadassah University Hospital, Jerusalem, Israel.
Cancer Genetics and Cytogenetics
|August 5, 1999
Summary
The 6;9 chromosomal translocation, typically linked to poor-prognosis leukemia, appears to have a different impact in myelodysplastic syndromes (MDS). Patients with MDS and t(6;9) show similar prognoses to other RAEB and RAEBt cases.
Area of Science:
- Hematology
- Oncology
- Cytogenetics
Background:
- The 6;9 chromosomal translocation [t(6;9)] is a known indicator of poor prognosis in acute nonlymphocytic leukemia.
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and a risk of transformation to acute leukemia.
Observation:
- This report details a case of refractory anemia with excess of blasts (RAEB) associated with the t(6;9) translocation.
- A literature review identified ten additional MDS patients with the t(6;9) translocation, who tended to be younger than the average MDS patient.
Findings:
- In contrast to its poor prognostic value in leukemia, the t(6;9) translocation in MDS patients did not appear to worsen the overall prognosis.
- Patients with MDS and t(6;9) exhibited prognoses comparable to those with RAEB and refractory anemia with excess of blasts in transformation (RAEBt).
Implications:
- The t(6;9) chromosomal aberration may not be an unfavorable prognostic factor in the context of myelodysplastic syndromes.
- Further research is warranted to fully elucidate the prognostic significance of t(6;9) in MDS and its potential impact on treatment strategies.